Live Streaming0.8 CE Credits
The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations
Hosted by Medscape, LLC
May 21, 2026 – Jun 18, 2026 Online / Virtual
About This Event
This activity provides clinicians with a deep dive into emerging phase 2/3 data on metastatic hormone-sensitive prostate cancer (mHSPC) treatment intensification. Learners will gain practical guidance on managing toxicity, drug-drug interactions, and risk-based therapy selection when transitioning from traditional monotherapy to evidence-based doublet and triplet combinations.
Registration & Fees
Continuing Education
0.8 CE Credits
Accredited by: ACCME
Activity offers AMA PRA Category 1 Credit (0.75 hours), Nursing (0.75 hours), and Pharmacy (0.75 hours) credits. Accredited by Medscape, LLC, an ACCME Innovation Partner.